
BioDiem and Griffith University secure grant to continue world class research in anti-microbial drug discovery

Griffith University's Institute for Glycomics in collaboration with BioDiem have been awarded a prestigious Australian Research Council Linkage grant of \$241,564, to investigate the role of the Biodiem's (BDM-I) technology in fighting infections.

The project's researchers Prof Yaoqi Zhou, Dr Joe Tiralongo and Dr Yuedong Yang aim to uncover the molecular targets of BDM-I, a novel antimicrobial candidate owned by BioDiem.

BioDiem Chief Executive Officer Julie Phillips said the exploration of BDM-I's mechanism of action in certain infections would assist in development of BDM-I products and add to its commercial attractiveness.

"The grant is a tremendous endorsement of the BDM-I technology and a wonderful opportunity to work with Griffith University, one of Australia's leading research universities," she said.

Institute for Glycomics Director Professor Mark von Itzstein said the grant enhanced the Institutes focus and commitment to ground breaking research.

"It also reflects the translational focus of our Institute and demonstrates our capacity to engage with industry partners such as BioDiem Ltd," he said.

This particular project, titled '*Novel antimicrobial target discovery by an integrated approach*', plans to show the first computational method to integrate target and ligand similarity for proteome-scale target and off-target discovery, which will advance the global fight against drug-resistant microorganisms.

Prof Yaoqi Zhou, lead investigator on the grant, said he was delighted with the award and is confident that he and his collaborators will significantly advance the understanding of how BDM-I targets microbial infections.

The BDM-I anti-infective technology is being developed, through BioDiem's subsidiary, Opal Biosciences, to develop products targeting serious human infections.

Opal will provide cash and in-kind contribution to the project, which will run for two years. Opal is currently raising funds to support the next stage of development of the BDM-I products which includes an injectable product and one which can be applied to the skin.

The Company's bonus offer under the fund raise, which involves the issue of 1 option for every 2 shares subscribed, closes next Wednesday, 15 July 2015.

Opal is also conducting investor presentations in Sydney on Monday, 13 July 2015 and in Melbourne on Tuesday, 14 July 2015 to present the key investment highlights of the Opal technology to investors. For further details please refer to <http://opalbiosciences.com/>

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.

About Griffith University's Institute for Glycomics

The Institute for Glycomics's unique research expertise makes it the only one of its kind in Australia and only one of a handful in the world.

It seeks to collaborate with leading scientists around the world to build a critical mass around this multidisciplinary research.